PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast - George L. Bakris, MD, FASN, FAHA - Recent Advances in the Management of Hyperkalemia: The Role of Newer Treatment Strategies to Improve Patient Outcomes

George L. Bakris, MD, FASN, FAHA - Recent Advances in the Management of Hyperkalemia: The Role of Newer Treatment Strategies to Improve Patient Outcomes

01/06/20 • 35 min

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/YPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses the risk factors and symptoms associated with hyperkalemia and provides strategies to identify and manage these patients as well as methods for incorporating newer treatment options based on the latest evidence. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical signs and symptoms associated with hyperkalemia, Identify different patient populations with or at risk for hyperkalemia and management strategies that address their specific needs and clinical goals of care, Incorporate newer treatment options for hyperkalemia management, including among patients with diabetes, heart failure, and chronic kidney disease (CKD), based on the latest evidence

Previous Episode

undefined - Lorinda Chung, MD, MS - Recognizing and Managing Progressive Fibrosing ILD in Patients With Connective Tissue Diseases: Examining the Potential Clinical Implications of Antifibrotic Therapy

Lorinda Chung, MD, MS - Recognizing and Managing Progressive Fibrosing ILD in Patients With Connective Tissue Diseases: Examining the Potential Clinical Implications of Antifibrotic Therapy

Go online to PeerView.com/ZBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung disease discuss the latest clinical evidence for the use of antifibrotic therapy for ILDs. Upon completion of this activity, participants should be better able to: Recognize the prevalence and risk of interstitial lung disease (ILD) in patients with connective tissue diseases (CTDs), including systemic sclerosis (SSc)-associated ILD, Identify signs, symptoms, and patterns of ILD with a progressive phenotype in patients with CTDs, including SSc-ILD, Review current management, including treatment and recommendations for monitoring, as well as the latest clinical evidence for the use of antifibrotic therapy for ILDs associated with a progressive phenotype such as SSc-ILD, Discuss the importance of a multidisciplinary approach that includes rheumatologists to the diagnosis and management of ILDs associated with CTDs

Next Episode

undefined - Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

Go online to PeerView.com/YNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients. Upon completion of this activity, participants should be better able to: Screen patients with or at high risk of CV disease for T2DM, Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity), Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM, Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM